Davide Frumento | Molecular Oncology | Best Researcher Award

Prof. Davide Frumento | Molecular Oncology | Best Researcher Award

Adjunct Professor, RomaTre University, Italy

Dr. Davide Frumento is an experienced academic and researcher currently serving as an adjunct professor at Roma Tre University and Milan University in Italy. With a strong background in chemical engineering and biotechnology, he has contributed extensively to the scientific community in various research fields. His multidisciplinary expertise bridges molecular oncology, epigenetics, and biotechnology. Passionate about advancing scientific knowledge, Dr. Frumento has worked in both academic and industry settings, collaborating with top-tier institutions like Harvard University. His research is focused on innovative solutions in health, biotechnology, and environmental sustainability.

Profile

Orcid

Education 

Dr. Davide Frumento holds a PhD in Chemical Engineering from Genoa University (2012-2015), where he specialized in biotechnology applications. He graduated with a BSc and MSc in Biotechnology from the same institution (2005-2011). He further broadened his qualifications with a certification as a Scientific Expert for Criminal Procedures Court of Savona (2024). His academic journey reflects a consistent commitment to advancing his knowledge and skills, particularly in molecular sciences. Throughout his career, Dr. Frumento has continuously expanded his expertise by engaging in postdoctoral research at prominent institutions, including the University of Genoa, Milan University, and Harvard University. His extensive education has laid a strong foundation for his contributions to both academia and the industry.

Experience

Dr. Frumento has a distinguished career in academia and research. Since February 2025, he has served as an adjunct professor at the Penitentiary University Center, Milan University. He also holds a position as an adjunct professor in Epigenetics at Roma Tre University, Italy, since 2021. Previously, he has worked as a postdoctoral researcher at Genoa University, San Raffaele Hospital, and Milan University, where he contributed to research in health sciences and biotechnology. His postdoctoral research has spanned multiple departments, including DISSAL, DIMES, and DIFAR, focusing on various aspects of molecular biology, microbiota, and immunology. Dr. Frumento’s industrial experience includes a role as a Quality Control Microbiology Analyst at Noberasco SpA, further showcasing his diverse professional background. His broad expertise in both academic and industry research makes him a significant contributor to the scientific community.

Awards and Honors

Dr. Frumento’s contributions to the scientific field have earned him several prestigious awards. Notably, in 2021, he received the Smart Cup Scientific Award for Innovation and Technology from Regione Liguria, recognizing his work in health and environmental technology implementation. Earlier, in 2014, he won the Start Cup Scientific Award from the University of Genoa for his innovative work on a microtubular photobioreactor, aimed at improving microalgae culture for commercial use. His dedication to scientific innovation is also reflected in his membership in multiple scientific and technical organizations, including STRA and the Research Data Alliance. Dr. Frumento’s recognition within both the academic and industry sectors highlights his commitment to advancing research in molecular sciences, biotechnology, and environmental sustainability.

Research Focus

Dr. Frumento’s research spans several cutting-edge areas of molecular biology, with particular emphasis on biotechnology, molecular oncology, epigenetics, and environmental sciences. His work on the human microbiota’s role in immune responses and diseases such as hepatitis C and multiple sclerosis has contributed significantly to understanding their interplay. Additionally, he has explored the role of sirtuins in autoimmunity, studying SIRT6 inhibition as a therapeutic strategy for multiple sclerosis and other autoimmune diseases. Dr. Frumento’s research in the application of light-based technologies in immunotherapy further highlights his focus on innovative solutions for health and disease management. His work extends to environmental sustainability, where he investigates biotechnological applications for waste management and bioengineering, particularly in areas such as microalgae culture. By blending molecular biology with practical applications in medicine and the environment, Dr. Frumento continues to push the boundaries of scientific discovery.

Publication Top Notes

  • Interaction Between Human Microbiota, Immune System, and Hepatitis C Virus Infection: A Narrative Review 🦠
  • Light-based technologies in immunotherapy: advances, mechanisms, and applications 💡
  • Effects of Wildfire Exposure on the Human Immune System 🔥🧬
  • Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment 💊
  • Health Technology Assessment (HTA) sull’introduzione di coorti aggiuntive per la vaccinazione contro il meningococco 🦠💉
  • Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration 🧠
  • E-Muser (Enhanced Multiple Sclerosis Expected Rate): A Technical Improvement 🧑‍🔬
  • Sarcoglycanopathies: A Novel Predictive Approach 🧬
  • SIRT6 inhibition as a therapeutic approach for treating multiple sclerosis 🧠💉
  • DAI (Disease Aggressiveness Index) Implementation 📊
  • MuSER (Multiple Sclerosis Expected Rate) Predictive Model Development 🧠📈
  • Gut Microbiota Role in Liver Regeneration 🦠💡
  • Microbiota and HCV Infection Interplay 🦠
  • Oral bacteria contribution in wine flavor perception 🍷🦠
  • The efficacy of the new anti HCV therapy, implementation of a path based on the logic of micro-elimination in the Department of Mental Health and Addictions ASL4 Chiavarese 💊

 

 

Stuart Maudsley | Receptor Pharmacology | Best Researcher Award

Prof. Dr. Stuart Maudsley | Receptor Pharmacology | Best Researcher Award

Senior Fellow/Professor, H. Lee Moffitt Cancer Center, United States

Dr. Stuart Russell Maudsley is a renowned pharmacologist with a distinguished career in receptor biology, specializing in therapeutic precision medicines targeting GPCRs (G-Protein Coupled Receptors). He is currently the Principal Investigator at the Maudsley Lab and a Senior Member at Moffitt Cancer Center. Dr. Maudsley is also a co-founder of HeptOME, focusing on aging-related diseases and metabolic dysfunction. With over two decades of research experience, he has held prominent roles including scientific advisor to the Belgian Superior Health Council, and various leadership roles at Johns Hopkins, the NIH, and VIB. His groundbreaking work includes receptor pharmacology and molecular biology studies aimed at advancing novel treatments for complex human disorders, particularly cancer and neurodegenerative diseases. His career has been recognized globally, earning numerous awards and honors for his contributions to molecular pharmacology.

Profile

Education

Dr. Stuart Russell Maudsley obtained his PhD in Pharmacology from the University of Leeds, UK, where he was awarded the Ackroyd, Brotherton & Brown Scholarship. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, marking the beginning of his illustrious career in receptor pharmacology. Prior to his PhD, Dr. Maudsley earned a First-Class B.Sc. in Pharmacology from the same institution. During his academic tenure, he engaged in advanced studies of ion channel electrophysiology and the pharmacology of the central nervous system, topics that have significantly shaped his subsequent research endeavors. His educational foundation laid the groundwork for his future contributions in both academia and the pharmaceutical industry, particularly in the development of novel therapeutic strategies for neurodegenerative diseases, cancer, and metabolic disorders.

Experience

Dr. Stuart Russell Maudsley boasts an extensive career with leadership roles across academia, industry, and government. He is the Principal Investigator at the Maudsley Lab at Moffitt Cancer Center and the co-founder of HeptOME, where he focuses on receptor-targeted therapies for aging-related metabolic diseases. Throughout his career, Dr. Maudsley has held various significant positions, including Adjunct Director at VIB, Vice-Chair at the University of Antwerp’s Department of Biomedical Science, and Principal Investigator at the NIH. He has contributed to numerous international projects, including his work as a Special Science Advisor to the Belgian Superior Health Council. Dr. Maudsley has also led scientific teams at Johnson & Johnson, the U.S. Department of Defense, and the NIH, where he made crucial contributions to drug development and the understanding of receptor pharmacology. His leadership and expertise have resulted in groundbreaking advancements in the pharmacology and therapeutics of complex diseases.

Awards and Honors

Dr. Stuart Russell Maudsley has received numerous prestigious awards and honors throughout his career. Notable recognitions include the 2021 UAntwerpen Seal of Excellence Grant, 2020 Johnson & Johnson Research Grant, and the 2019 FWO Doctoral Research Grant. He has also been honored with the FWO Senior Research Fellows Grant and the UAntwerpen-IOF Industrial Collaboration Research Grant in 2019. His work in molecular pharmacology and receptor biology has led to the receipt of multiple awards from both European and American institutions, including the National Institutes of Health On-the-Spot Award (2011-2013). Dr. Maudsley’s groundbreaking research on neurodegenerative diseases, aging, and metabolic dysfunction has earned him widespread recognition in the scientific community. His scientific excellence and contributions to pharmacology, drug discovery, and biotechnology continue to inspire advancements in the treatment of complex human disorders.

Research Focus

Dr. Stuart Russell Maudsley’s research primarily focuses on receptor pharmacology, with a special emphasis on G-Protein Coupled Receptors (GPCRs) and their role in human disease. His work seeks to identify and develop precision GPCR-targeted therapies for cancer, neurodegenerative disorders, and metabolic diseases such as obesity and aging-related conditions. Through his leadership in both academic labs and the biotech industry, Dr. Maudsley investigates novel biotechnological platforms, including both wet and dry biomedical technologies. He aims to create multidimensional precision medicines that can more effectively treat complex disorders, particularly those related to aging. His current research in the Maudsley Lab centers on the molecular mechanisms that underlie aging and neurodegenerative diseases, as well as the identification of potential therapeutic agents. By exploring the intricate signaling pathways of GPCRs, Dr. Maudsley is paving the way for the development of innovative treatments for diseases that currently lack effective therapies.

Publications Top Notes

  • β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes – Science (1999) 🧬📚
  • BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders – Trends in Neurosciences (2004) 🧠
  • The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women – International Journal of Obesity (2011) 🍏🏃‍♀️
  • Gonadotropin-releasing hormone receptors – Endocrine Reviews (2004) 💊🔬
  • Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma – Free Radical Biology and Medicine (2007) 🏥
  • Caloric restriction and intermittent fasting: two potential diets for successful brain aging – Ageing Research Reviews (2006) 🧠
  • The β2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor – Journal of Biological Chemistry (2000) 🧬🔬